NICE TA294: injection for treating
wet age-related macular degeneration. (Decision date - August 2013)
NICE TA305: for visual impairment
caused by macular oedema secondary to CRVO. (Decision date - March 2014)
NICE TA346: for treating diabetic macular oedema. (Decision date - August 2015)
NICE TA409: for visual impairment
caused by macular oedema after branch retinal vein occlusion. (Decision
date - October 2016)
NICE TA486: for treating choroidal neovascularisation. (Decision date - December 2017).
Do Not Prescribe (DNP)
NICE TA307: Aflibercept in
combination with irinotecan and fluorouracil-based therapy for treating
metastatic colorectal cancer that has progressed following prior
oxaliplatin-based chemotherapy. (Aflibercept can be funded through the cancer drug fund for this indication. Seek advice from the oncologist/haematologist). (Decision date - April 2014).
Do Not Prescribe (DNP) Drug Classifications
6: Have NICE guidance that recommends they should not be used
Red Drug Classifications
1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)
